肝硬化对氯美噻唑药代动力学的影响。
Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.
作者信息
Pentikainen P J, Neuvonen P J, Tarpila S, Syvälahti E
出版信息
Br Med J. 1978 Sep 23;2(6141):861-3. doi: 10.1136/bmj.2.6141.861.
Abstract
The pharmacokinetics of chlormethiazole were studied in eight patients with advanced cirrhosis of the liver and in six healthy volunteers after oral and intravenous administration of the drug. In the patients the systemic bioavailability of oral chlormethiazole was increased about tenfold, whereas its elimination was only slightly retarded. The increased bioavailability was clearly due to decreased first-pass metabolism of chlormethiazole in the cirrhotic liver. The results indicate that chlormethiazole should be used in reduced dosage when given by mouth to patients with cirrhosis of the liver.
摘要
在8例晚期肝硬化患者和6名健康志愿者口服及静脉注射氯美噻唑后，对其药代动力学进行了研究。在患者中，口服氯美噻唑的全身生物利用度提高了约10倍，而其消除仅略有延迟。生物利用度增加显然是由于肝硬化肝脏中氯美噻唑的首过代谢减少。结果表明，给肝硬化患者口服氯美噻唑时应减少剂量。
相似文献
1
Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.肝硬化对氯美噻唑药代动力学的影响。
Br Med J. 1978 Sep 23;2(6141):861-3. doi: 10.1136/bmj.2.6141.861.
2
Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver.氯美噻唑在健康志愿者和肝硬化患者中的药代动力学。
Eur J Clin Pharmacol. 1980 Apr;17(4):275-84. doi: 10.1007/BF00625801.
3
Pharmacokinetics of chlormethiazole in humans.氯美噻唑在人体内的药代动力学。
Eur J Clin Pharmacol. 1975 Jun 13;8(5):353-7. doi: 10.1007/BF00562662.
4
Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
Aust N Z J Med. 1980 Oct;10(5):515-9. doi: 10.1111/j.1445-5994.1980.tb04969.x.
5
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.
Clin Pharmacol Ther. 1990 Mar;47(3):354-9. doi: 10.1038/clpt.1990.39.
6
Cimetidine clearance and bioavailability in hepatic cirrhosis.西咪替丁在肝硬化中的清除率和生物利用度。
Clin Pharmacol Ther. 1981 Feb;29(2):191-7. doi: 10.1038/clpt.1981.30.
7
The effect of ethanol administration on the disposition and elimination of chlormethiazole.乙醇给药对氯美噻唑处置和消除的影响。
Eur J Clin Pharmacol. 1983;24(3):383-5. doi: 10.1007/BF00610059.
8
Flumazenil disposition and elimination in cirrhosis.
Clin Pharmacol Ther. 1989 Sep;46(3):317-23. doi: 10.1038/clpt.1989.145.
9
Cimetidine impairs the elimination of chlormethiazole.西咪替丁会损害氯美噻唑的消除。
Eur J Clin Pharmacol. 1981;21(1):83-5. doi: 10.1007/BF00609593.
10
Pharmacokinetics of metoclopramide in patients with liver cirrhosis.肝硬化患者中甲氧氯普胺的药代动力学
Br J Clin Pharmacol. 1991 Feb;31(2):185-7. doi: 10.1111/j.1365-2125.1991.tb05511.x.
引用本文的文献
1
Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.同时使用口服氯唑沙宗和咪达唑仑微剂量进行 CYP2E1 和 CYP3A 的表型分析。
Br J Clin Pharmacol. 2019 Oct;85(10):2310-2320. doi: 10.1111/bcp.14040. Epub 2019 Aug 9.
2
Pharmacokinetic considerations in clinical toxicology: clinical applications.临床毒理学中的药代动力学考量：临床应用
Clin Pharmacokinet. 2007;46(11):897-939. doi: 10.2165/00003088-200746110-00001.
3
Individual variation in first-pass metabolism.首过代谢的个体差异。
Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.
4
An integrated study of pharmacokinetics and pharmacodynamics of chlormethiazole in healthy young volunteers.氯美噻唑在健康青年志愿者体内的药代动力学和药效学综合研究。
Eur J Clin Pharmacol. 1981 Mar;19(4):263-9. doi: 10.1007/BF00562803.
5
Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver.氯美噻唑在健康志愿者和肝硬化患者中的药代动力学。
Eur J Clin Pharmacol. 1980 Apr;17(4):275-84. doi: 10.1007/BF00625801.
6
Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.新型催眠药佐匹克隆在慢性肝病患者中的血浆浓度及对中枢神经系统的影响。
Br J Clin Pharmacol. 1983 Sep;16(3):259-65. doi: 10.1111/j.1365-2125.1983.tb02159.x.
7
First-pass elimination. Basic concepts and clinical consequences.首过消除。基本概念及临床后果。
Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001.
8
Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
Eur J Clin Pharmacol. 1986;30(4):407-16. doi: 10.1007/BF00607952.
9
The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.危重症患者常用药物的药代动力学和药效学改变。
Clin Pharmacokinet. 1988 Jun;14(6):347-73. doi: 10.2165/00003088-198814060-00003.
10
Chlormethiazole and alcohol: a lethal cocktail.氯美噻唑与酒精：致命组合。
Br Med J (Clin Res Ed). 1987 Mar 7;294(6572):592. doi: 10.1136/bmj.294.6572.592.
本文引用的文献
1
The disposition of propranolol. I. Elimination during oral absorption in man.普萘洛尔的处置。I. 人体口服吸收过程中的消除
Pharmacology. 1972;7(3):159-68. doi: 10.1159/000136285.
2
Commentary: a physiological approach to hepatic drug clearance.述评：肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.
3
Deaths in connection with chlormethiazole (heminevrin) therapy.
Int J Clin Pharmacol Biopharm. 1976 Oct;14(3):225-30.
4
Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations.氯美噻唑在有酒精戒断表现患者中的药代动力学
Clin Pharmacol Ther. 1978 Feb;23(2):181-7. doi: 10.1002/cpt1978232181.
Zotero 插件